Cargando…
Intepirdine as adjunctive therapy to donepezil for mild‐to‐moderate Alzheimer's disease: A randomized, placebo‐controlled, phase 3 clinical trial (MINDSET)
INTRODUCTION: A previous phase 2b study supported the use of the 5‐HT6 receptor antagonist intepirdine as adjunctive therapy to donepezil for Alzheimer's disease (AD) dementia. A phase 3 study, MINDSET, was performed to test this hypothesis. METHODS: MINDSET was a global, double‐blind, randomiz...
Autores principales: | Lang, Frederick M., Mo, Yi, Sabbagh, Marwan, Solomon, Paul, Boada, Merce, Jones, Roy W., Frisoni, Giovanni B., Grimmer, Timo, Dubois, Bruno, Harnett, Mark, Friedhoff, Sarah R., Coslett, Shari, Cummings, Jeffrey L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165732/ https://www.ncbi.nlm.nih.gov/pubmed/34095437 http://dx.doi.org/10.1002/trc2.12136 |
Ejemplares similares
-
An international, randomized, placebo‐controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY‐DLB)
por: Lang, Frederick M., et al.
Publicado: (2021) -
Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
por: Sabbagh, Marwan, et al.
Publicado: (2011) -
Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease
por: Berk, Camryn, et al.
Publicado: (2012) -
Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil
por: Ortner, Marion, et al.
Publicado: (2020) -
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
por: Sabbagh, Marwan, et al.
Publicado: (2013)